GRACEcast

By Howard (Jack) West, MD

Expert oncologists provide brief, distilled summaries of the most central issues in cancer management and emerging approaches for patients and caregivers. The Global Resource for Advancing Cancer Edu... more

Download on the App Store

Download on the App Store

Get it on Google Play

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.

GRACEcast episodes:

July 11, 2013 Dr. Bob Doebele on the Most Promising Upcoming New Targeted Agents and Molecular Pathways for Lung Cancer Treatment
Dr. Bob Doebele from the University of Colorado, provides his view on the targeted therapy approaches most likely to become clinically useful in lung cancer over the next several years.
...more
3min
July 11, 2013 Drs. Ross Camidge and Corey Langer on "Which patients do you send molecular marker testing for?"
Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.
...more
5min
July 11, 2013 Dr. Greg Riely: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?
Dr. Greg Riely, from Memorial Sloan-Kettering, gives her view on more widespread availability of new mutation tests.
...more
3min
July 04, 2013 Is there a place for maintenance therapy in extensive stage NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss whether the finding of improving progression-free survival with maintenance sorafenib for SCLC should change the standard of care for treatment of extensive stage disease.
...more
5min
July 04, 2013 How should we integrate new immunotherapies into treatment strategies for lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell review various ways in which emerging immunotherapies could be effectively incorporated into our treatment strategies for lung cancer, potentially adding to or replacing current options.
...more
5min
July 04, 2013 How do we approach acquired resistance to targeted therapies in lung cancer?
Drs. Jack West, Mary Pinder, and Nate Pennell discuss options for managing acquired resistance to EGFR TKIs and ALK inhibitors in patients with advanced NSCLC and a driver mutation.
...more
6min
July 04, 2013 What have we learned from the START trial of immunotherapy in locally advanced NSCLC?
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.
...more
3min
July 04, 2013 Dr. Phil Bonomi: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy
Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.
...more
1min
July 04, 2013 Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?
Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.
...more
2min
July 02, 2013 Can we target KRAS effectively in advanced NSCLC?
Drs. Mary Pinder, Nate Pennell, and Jack West discuss developments with selumetinib and other MEK inhibitors as a potential target for the 20-25% of NSCLC patients with a KRAS mutation.
...more
5min

FAQs about GRACEcast:

How many episodes does GRACEcast have?

The podcast currently has 625 episodes available.